Difference between revisions of "Chidamide (Epidaza)"
Jump to navigation
Jump to search
m |
m |
||
| Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Breast cancer]] | ||
*[[Peripheral T-cell lymphoma]] | *[[Peripheral T-cell lymphoma]] | ||
| Line 16: | Line 17: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:HDAC inhibitors]] | [[Category:HDAC inhibitors]] | ||
| + | |||
| + | [[Category:Breast cancer medications]] | ||
[[Category:Peripheral T-cell lymphoma medications]] | [[Category:Peripheral T-cell lymphoma medications]] | ||
[[Category:CFDA approved drugs]] | [[Category:CFDA approved drugs]] | ||
Revision as of 02:48, 7 June 2019
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable benzamide type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Tucidinostat selectively binds to and inhibits HDAC leading to an increase of acetylation levels of histone protein H3. This agent also inhibits the expression of signaling kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells.
Diseases for which it is used
History of changes in FDA indication
Not FDA approved, but is approved for use in China.
Also known as
- Code names: CS055, HBI-8000
- Generic name: tucidinostat
- Brand name: Epidaza